JavaScript seems to be disabled in your browser. You must have JavaScript enabled in your browser to utilize the functionality of this website.
Description: Glecaprevir (previously known as ABT-493 and/or A-1282576; trade name: Mavyret) is a novel and potent inhibitor of the HCV NS3/4A protease (HCV: hepatitis C virus; NS: nonstructural) with IC50 ranging from 3.5 to 11.3 nM. Glecaprevir has the potential to be used as an anti-HCV agent and is currently undergoing phase 3 clinical trials for HCV treatment by AbbVie. Glecaprevir is a direct-acting antiviral (DAA) which demonstrated potent antiviral activity against major HCV genotypes and high barriers to resistance in vitro. It also exhibited an acceptable safety profile during a 3-day monotherapy in patients with HCV genotype 1 infection, with or without compensated cirrhosis. In August 2017, the U.S. Food and Drug Administration approved the combination drug glecaprevir/pibrentasvir (trade name Mavyret) for the treatment of all major genotypes (1–6) of chronic hepatitis C.
References: Antimicrob Agents Chemother. 2017; 62(1). pii: e01620-17; Antimicrob Agents Chemother. 2015; 60(3):1546-55.
Related CAS#: 1838572-01-2 (hydrate)
Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.
All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.
Request Data Sheet
Request product datasheet
Request safety datasheet
Compare
Add to wishlist
Recommend by mail
Get an offer
Request delivery time
Ask a technical question
Submit a bulk request
sales@hoelzel.de
« Back
Subscribe, get 15% off every fifth order and have your items delivered on time!
Forgot Your Password?
Not yet registered? Create account here!